Posted by: Salvatore J. Zambri, founding partner
Bloomberg News reported that “Novartis AG and Orion Oyj’s Stalevo treatment for Parkinson’s disease may be linked to an increased risk of prostate cancer, US health regulators said.” In a statement found on its website, the FDA states that its “review of Stalevo is ongoing, and no new conclusions or recommendations about the use of this drug have been made.” The agency “is reviewing a clinical trial that showed that prostate cancer was more common among patients taking Stalevo than in those taking only a combination of carbidopa and levodopa.”
If you have been prescribed Stalevo, we encourage you to speak to your doctor promptly about all potential risks and benefits. Your doctor is obligated to provide this information to you so that you can make the best, most informed, decisions possible concerning your health.
I’ll report back once we learn more about the FDA’s review of the clinical trial. In the meantime, if you have any questions at all, please feel free to contact me.
About the author:
Mr. Zambri is a Past-President of the Trial Lawyers Association of Metropolitan Washington, D.C. He has been acknowledged by Washingtonian magazine as a “Big Gun” and among the “top 1%” of all of the more than 80,000 lawyers in the Washington metropolitan area. The magazine also acknowledges him as “one of Washington’s best–most honest and effective lawyers” who specializes in medical malpractice matters, product liability claims, and serious automobile accident claims. Mr. Zambri has also been repeatedly named a “Super Lawyer” by Law and Politics magazine–a national publication that honors the top lawyers in America.
Mr. Zambri is regularly asked to present seminars to lawyers and doctors, as well as both medical and law students concerning medication errors, medical malpractice litigation, and safety improvements.